Michael Korn, MD

Articles by Michael Korn, MD

Infusional 5-FU, Folinic Acid, Paclitaxel, and Cisplatin for Metastatic

ByUte Klaassen, MD,Hans Jochen Wilke, MD,Christian Müller, MD,David Borquez, MD,Michael Korn, MD,Klaus Diergarten, MD,Siegfried Seeber, MD, PhD

April 1st 1997

Our phase II study results demonstrating high efficacy and low toxicity for a weekly schedule of high-dose, 24-hour infusional 5-fluorouracil(5-FU)/folinic acid (HD5-FU/FA) in intensively pretreated patients with metastatic

Latest Updated Articles

Infusional 5-FU, Folinic Acid, Paclitaxel, and Cisplatin for Metastatic
April 1st 1997

Michael Korn, MD

Articles by Michael Korn, MD

Infusional 5-FU, Folinic Acid, Paclitaxel, and Cisplatin for Metastatic

Latest Updated Articles

Trending on CancerNetwork

FDA ODAC Votes No to Camizestrant for HR+/HER2– ESR1 Advanced Breast Cancer

Targeting KRAS in Pancreatic Cancer: What is Daraxonrasib’s Mechanism of Action?

FDA ODAC Votes Yes to Capivasertib for PTEN-Deficient Metastatic HSPC

FDA Grants Priority Review to Tislelizumab/Zanidatamab in 1L HER2+ Gastric Cancers

Simlukafusp Alfa Combo Shows Promising Early Efficacy in Unresectable RCC